ADvantage Therapeutics

ADvantage Therapeutics is pioneering a novel immunotherapy approach for Alzheimer's Disease with its lead candidate, AD04™, a compound with an established safety profile from its prior use as a vaccine adjuvant. Unexpected Phase 2 data revealed AD04™ significantly slowed cognitive decline and hippocampal atrophy in early AD patients, forming the basis for the company's founding. The company is now advancing AD04™ into further Phase 2 trials in Europe, supported by an MHRA ILAP Passport in the UK, which could enable early commercialization. ADvantage's pipeline also includes research into the longevity protein Klotho, aiming to develop first-in-class therapeutics for diseases of aging.

Immunomodulation via repurposed vaccine adjuvants to induce a peripheral immune response that translates to reduced neuroinflammation and enhanced clearance of toxic waste molecules in the brain.

ADvantage competes in the Alzheimer's space dominated by large pharma (Biogen/Eisai, Lilly) with approved anti-amyloid antibodies. Its differentiation lies in a potentially safer, immunomodulatory mechanism versus direct targeting of amyloid or tau. Success depends on demonstrating comparable or superior efficacy with a better safety/tolerability profile.